YMAB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
YMAB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Y-mAbs Therapeutics's annualized ROCE % for the quarter that ended in Dec. 2023 was -11.91%.
The historical data trend for Y-mAbs Therapeutics's ROCE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Y-mAbs Therapeutics Annual Data | |||||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
ROCE % | Get a 7-Day Free Trial | -48.04 | -76.08 | -35.92 | -63.61 | -23.24 |
Y-mAbs Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
ROCE % | Get a 7-Day Free Trial | -4.10 | -26.71 | -26.30 | -28.80 | -11.91 |
Y-mAbs Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:
ROCE % | = | EBIT | / | ( (Capital Employed | + | Capital Employed) | / count ) |
(A: Dec. 2023 ) | (A: Dec. 2022 ) | (A: Dec. 2023 ) | |||||
= | EBIT | / | ( ( (Total Assets - Total Current Liabilities) | + | (Total Assets - Total Current Liabilities) ) | / count ) | |
(A: Dec. 2023 ) | (A: Dec. 2022 ) | (A: Dec. 2023 ) | |||||
= | -25.672 | / | ( ( (141.456 - 28.284) | + | (127.869 - 20.128) ) | / 2 ) | |
= | -25.672 | / | ( (113.172 | + | 107.741) | / 2 ) | |
= | -25.672 | / | 110.4565 | ||||
= | -23.24 % |
Y-mAbs Therapeutics's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:
ROCE % | = | EBIT (1) | / | ( (Capital Employed | + | Capital Employed) | / count ) |
(Q: Dec. 2023 ) | (Q: Sep. 2023 ) | (Q: Dec. 2023 ) | |||||
= | EBIT | / | ( ( (Total Assets - Total Current Liabilities) | + | (Total Assets - Total Current Liabilities) ) | / count ) | |
(Q: Dec. 2023 ) | (Q: Sep. 2023 ) | (Q: Dec. 2023 ) | |||||
= | -12.796 | / | ( ( (128.884 - 21.812) | + | (127.869 - 20.128) ) | / 2 ) | |
= | -12.796 | / | ( ( 107.072 | + | 107.741 ) | / 2 ) | |
= | -12.796 | / | 107.4065 | ||||
= | -11.91 % |
(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Y-mAbs Therapeutics (NAS:YMAB) ROCE % Explanation
ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.
Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.
Thank you for viewing the detailed overview of Y-mAbs Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.
Thomas Gad | director, officer: President and Chairman | C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169 |
Biotech Aps Wg | 10 percent owner | RUNGSTED STRANDVEJ 113, RUNGSTED KYST G7 2960 |
Johan Wedell-wedellsborg | director, 10 percent owner | RUNGSTED STRANDVEJ 113, RUNGSTED KYST G7 2960 |
Michael J Rossi | director, officer: President & CEO | 230 PARK AVENUE, SUITE 3350, NEW YORK NY 10169 |
Vignesh Rajah | officer: SVP and CMO | HENRIKSHOJ 8, ROOM 4, VEDBAEK G7 DK-2950 |
Bo Kruse | director, officer: EVP, CFO, Secy & Treas. | C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169 |
Susan Laura Smith | officer: Senior Vice President, CCO | 5 OVERLOOK CT, LAMBERTVILLE NJ 08530 |
David N Gill | director | C/O NXSTAGE MEDICAL INC. (NXTM), 439 SOUTH UNION STREET, 5TH FLOOR, LAWRENCE MA 01843 |
Juan Moller San Pedro Claus | director, officer: Chief Executive Officer | C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3500, NEW YORK NY 10169 |
Laura Hamill | director | 333 LAKESIDE DRIVE, FOSTER CITY CA 94404 |
Mahiuddin Ahmed | officer: Sr. VP and CSO | C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3350, NEW YORK NY 10169 |
Philip Karl Herman | officer: Sr. VP and CCO | C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3350, NEW YORK NY 10169 |
James Healy | director | 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025 |
Gregory S Raskin | director | C/O MEMORIAL SLOAN KETTERING CANCER CENT, 1275 YORK AVENUE, BOX 524, NEW YORK NY 10065 |
Gerard Ber | director | C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169 |
From GuruFocus
By Marketwired • 09-21-2023
By sperokesalga sperokesalga • 03-20-2023
By Marketwired • 10-16-2023
By Marketwired • 10-23-2023
By Marketwired • 10-31-2023
By PRNewswire PRNewswire • 03-17-2023
By sperokesalga sperokesalga • 05-08-2023
By sperokesalga sperokesalga • 04-28-2023
By GuruFocus Research • 12-01-2023
By Business Wire Business Wire • 03-17-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.